Effects of Resveratrol on Ovarian Morphology,Plasma Anti-Mullerian Hormone,IGF-1 Levels,and Oxidative Stress Parameters in a Rat Model of Polycystic Ovary Syndrome
Restricted accessResearch articleFirst published online August, 2015
Effects of Resveratrol on Ovarian Morphology,Plasma Anti-Mullerian Hormone,IGF-1 Levels,and Oxidative Stress Parameters in a Rat Model of Polycystic Ovary Syndrome
To evaluate the effects of resveratrol in a rat model of polycystic ovarian syndrome (PCOS).
Study Design:
After PCOS model was formed by subcutaneous dihydrotestosterone pellets, rats were randomly divided into 2 groups. The first group (n = 7) was treated with 1 mL/kg/d isotonic saline and the second group (n = 7) was treated with 10 mg/kg/d resveratrol. Seven rats were taken as controls without any medication.
Results:
Our results showed (1) significant reduction in the number of antral follicle counts (P < .01); (2) significantly decreased plasma anti-Mullerian hormone and insulin-like growth factor 1 levels (P < .01 and P < .05, respectively); (3) significantly lower superoxide dismutase activity (P < .05); and (4) significantly increased glutathione peroxidase content (P < .01) following resveratrol treatment.
Conclusion:
Resveratrol appears to be effective in the treatment of PCOS due to its antioxidant properties. Future clinical studies with different dosages might provide useful implementations to our practice.
DunaifAThomasA. Current concepts in the polycystic ovary syndrome. Annu Rev Med. 2001;52:401–419.
2.
ChangWYKnochenhauerESBartolucciAAAzzizR. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril. 2005;83(6):1717–1723.
3.
MoranLJMissoMLWildRANormanRJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010;16(4):347–363.
4.
BoomsmaCMEijkemansMJHughesEGVisserGHFauserBCMacklonNS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update. 2006;12(6):673–683.
5.
RoosNKielerHSahlinLEkman-OrdebergGFalconerHStephanssonO. Risk of adverse pregnancy outcomes in women with polycystic ovary syndrome: population based cohort study. BMJ. 2011;343:d6309.
6.
WangJGNakhudaGSGuarnacciaMMSauerMVLoboRA. Müllerian inhibiting substance and disrupted folliculogenesis in polycystic ovary syndrome. Am J Obstet Gynecol. 2007;196
(1):77.e1–e5.
7.
SomunkiranAYavuzTYucelOOzdemirI. Anti-Müllerian hormone levels during hormonal contraception in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2007;134
(2):196–201.
8.
De MeytsERJorgensenNGraemNMullerJCateRLSkakkebaekNE. Expression of anti-Mullerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. J Clin Endocrinol Metab. 1999;84(10):3836–3844.
9.
de VetALavenJSde JongFHThemmenAPFauserBC. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril. 2002;77(2):357–362.
10.
BroekmansFJVisserJALavenJSBroerSLThemmenAPFauserBC. Anti-Mullerian hormone and ovarian dysfunction. Trends Endocrinol Metab. 2008;19(9):340–347.
11.
EilertsenTBVankyECarlsenSM. Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced?Hum Reprod. 2012;27
(8):2494–2502.
12.
IliodromitiSKelseyTWAndersonRANelsonSM. Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data. J Clin Endocrinol Metab. 2013;98
(8):3332–3340.
13.
LoucksTLTalbottEOMcHughKPKeelanMBergaSLGuzickDS. Do polycystic-appearing ovaries affect the risk of cardiovascular disease among women with polycystic ovary syndrome?Fertil Steril. 2000;74
(3):547–552.
14.
GuzickDSTalbottEOSutton-TyrrellKHerzogHCKullerLHWolfsonSK. Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Am J Obstet Gynecol. 1996;174
(4):1224–1229.
15.
SabuncuTVuralHHarmaMHarmaM. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem. 2001;34
(5):407–413.
16.
ShiYCuiYSunX. Hypertension in women with polycystic ovary syndrome: prevalence and associated cardiovascular risk factors. Eur J Obstet Gynecol Reprod Biol. 2014;173:66–70.
17.
GonzálezFRoteNSMiniumJKirwanJP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91
(1):336–340.
18.
DrögeW. Free radicals in the physiological control of cell function. Physiol Rev. 2002;82
(1):47–95.
19.
DringenRHamprechtB. Glutathione content as an indicator for the presence of metabolic pathways of amino acids in astroglial cultures. J Neurochem. 1996;67
(4):1375–1382.
20.
BaurJASinclairDA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5
(6):493–506.
JangMCaiLUdeaniGO. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997;275
(5297):218–220.
23.
RodrigoRBoscoC. Oxidative stress and protective effects of polyphenols: comparative studies in human and rodent kidney. A review. Comp Biochem Physiol C Toxicol Pharmacol. 2006;142
(3-4):317–327.
24.
PetrovskiGGurusamyNDasDK. Resveratrol in cardiovascular health and disease. Ann N Y Acad Sci. 2011;1215:22–33.
25.
ManneråsLCajanderSHolmängA. A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. Endocrinology. 2007;148
(8):3781–3791.
26.
FassnachtMSchlenzNSchneiderSBWudySAAllolioBArltW. Beyond adrenal and ovarian androgen generation: increased peripheral 5α-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88
(6):2760–2766.
27.
SilfenMEDenburgMRManiboAM. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between non-obese and obese adolescents. J Clin Endocrinol Metab. 2003;88(10):4682–4688.
28.
ErgenoğluAMYenielAÖErbaşO. Regression of endometrial implants by resveratrol in an experimentally induced endometriosis model in rats. Reprod Sci. 2013;20
(10):1230–1236.
29.
BusquetsSAmetllerEFusterG. Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer Lett. 2007;245
(1-2):144–148.
SunYOberleyLLiY. A simple method for clinical assay of superoxide dismutase. Clin Chem. 1988;34
(3):497–500.
32.
AebiH. Catalase in vitro. Methods Enzymol. 1984;105:121–126.
33.
BradfordMM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–254.
34.
DunaifAThomasA. Current concepts in the polycystic ovary syndrome. Annu Rev Med. 2001;52:401–419.
35.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–47.
36.
SahmaySAtakulNAydoganBAydinYImamogluMSeyisogluH. Elevated serum levels of anti-Müllerian hormone can be introduced as a new diagnostic marker for polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2013;92
(12):1369–1374.
37.
WongDHVillanuevaJACressABDulebaAJ. Effects of resveratrol on proliferation and apoptosis in rat ovarian theca-interstitial cells. Mol Hum Reprod. 2010;16
(4):251–259.
38.
OrtegaIVillanuevaJAWongDH. Resveratrol potentiates effects of simvastatin on inhibition of rat ovarian theca-interstitial cells steroidogenesis. J Ovarian Res. 2014;7
(1):21.
39.
BerkerBEmralRDemirelCCorapciogluDUnluCKoseK. Increased insulin-like growth factor-I levels in women with polycystic ovary syndrome, and beneficial effects of metformin therapy. Gynecol Endocrinol. 2004;19
(3):125–133.
40.
VanamalaJReddivariLRadhakrishnanSTarverC. Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer. 2010;10:238.
41.
RajendranSWilloughbySRChanWP. Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects. Atherosclerosis. 2009;204
(2):509–514.
42.
VictorVMRochaMBañulsC. Induction of oxidative stress and human leukocyte/endothelial cell interactions in polycystic ovary syndrome patients with insulin resistance. J Clin Endocrinol Metab. 2011;96
(10):3115–3122.
43.
BigfordGEDel RossiG. Supplemental substances derived from foods as adjunctive therapeutic agents for treatment of neurodegenerative diseases and disorders. Adv Nutr. 2014;5
(4):394–403.
SinghCKNdiayeMAAhmadN. Resveratrol and cancer: challenges for clinical translation[published online November 8, 2014.]. Biochim Biophys Acta. 2014. pii: S0925–4439(14)00334-2.
46.
RubioloJAMithieuxGVegaFV. Resveratrol protects primary rat hepatocytes against oxidative stress damage: activation of the Nrf2 transcription factor and augmented activities of antioxidant enzymes. Eur J Pharmacol. 2008;591
(1-3):66–72.
47.
López-VélezMMartínez-MartínezFDel Valle-RibesC. The study of phenolic compounds as natural antioxidants in wine. Crit Rev Food Sci Nutr. 2003;43
(3):233–244.
48.
ShinSMChoIJKimSG. Resveratrol protects mitochondria against oxidative stress through AMP-activated protein kinase-mediated glycogen synthase kinase-3beta inhibition downstream of poly(ADP-ribose)polymerase-LKB1 pathway. Mol Pharmacol. 2009;76
(4):884–895.
